Anti-HIV-1 activity of calanolides used in combination with other mechanistically diverse inhibitors of HIV-1 replication

Antiviral Chemistry and Chemotherapy

Volumn 11, Issue 5, 2000, Pages 321-327

  Buckheit R W , Jr ^a   Russell, J D ^a   Xu, Z Q ^a   Flavin, M ^a  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

Antivirals; HIV 1; NNRTIs

Indexed keywords

12 OXO CALANOLIDE A; ANTIRETROVIRUS AGENT; CALANOLIDE A; CALANOLIDE B; DIDANOSINE; DIHYDROCOSTATOLIDE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RESOBENE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; THIOCARBOXANILIDE; UC 10; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ANTAGONISM; DRUG DETERMINATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; STRAIN DIFFERENCE; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 0034529307     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020001100502     Document Type: Article

References (28)

1. Targeting HIV reverse transcriptase for anti-AIDS drug design; structural and biological considerations for chemotherapeutic strategies
2. Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent
3. The thiocarboxanilide nonnucleoside UC781 is a tight-binding inhibitor of HIV-1 reverse transcriptase
4. CD4-Pseudomonas exotoxin hybrid protein blocks the spread of human immunodeficiency virus infection in vitro and is active against cells expressing the envelope glycoproteins from diverse primate immunodeficiency retroviruses
5. HIV-1 drug resistance in newly infected individuals
6. Combinations of AZT and analogs of TIBO act synergistically to inhibit HIV-1 infection in vitro
7. Activity of selected anti-HIV agents in combination with AZT and ddI
8. Thiazolobenzimidazole: Biological and biochemical anti- retroviral activity of a new nonnucleoside reverse transcriptase inhibitor
9. Cell based and biochemical analysis of the anti-HIV activity of combinations of 3′-azido-3′-deoxythymidine and analogs of TIBO
10. Biological and biochemical anti-HIV activity of the benzothiadiazine class of nonnucleoside reverse transcriptase inhibitors
11. Comparative anti-HIV evaluation of diverse HIV-1-specific reverse transcriptase inhibitor-resistant virus isolates demonstrates the existence of distinct phenotypic subgroups
12. Unique anti-human immunodeficiency virus activities of the non-nucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide
13. Antiviral activity and mechanism of action of calanolide A against the human immunodeficiency virus type-1
14. Kinetic analysis of inhibition of human immunodeficiency virus type 1 reverse transcriptase by calanolide A
15. Synthesis, chromatographic resolution and anti-HIV activity (+)-calanolide A and its enantiomers
16. The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum
17. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
18. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection
19. Specific inhibition of human immunodeficiency virus type 1 reverse transcriptase mediated by soulattrolide, a coumarine isolated from the latex of Calophyllum teysmannii
20. A three-dimensional model to analyze drug-drug interactions
21. Sensitivity and resistance to (+)-calanolide A of wild-type and mutated forms of HIV-1 reverse transcriptase
22. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study
23. Recombinant retroviral systems for the analysis of drug resistant HIV
24. Summary of the III International Consensus Symposium on Combined Antiviral Therapy
25. In vivo anti-HIV activity of (+)-calanolide A in the hollow fiber mouse model
26. Plant-derived and semi-synthetic calanolide compounds with in vitro activity against both human immunodeficiency virus type 1 and human cytomegalovirus
27. Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti-human immunodeficiency virus activity
28. Transmission of antiretroviral-drug-resistant HIV-1 variants